Archives
-
DiscoveryProbe Library: Scope and Evidence
2026-10-14
The DiscoveryProbe™ Bioactive Compound Library Plus is described by APExBIO as a 5,072-compound, research-use-only collection spanning multiple biological pathway classes. Its documented value is breadth and standardized product presentation, not a single shared mechanism or demonstrated outcome in a matched study. The supplied record contains no identity-matched research paper, effect sizes, assay results, or independent validation of product performance.
-
Phalloidin: Identity and Evidence Boundaries
2026-10-14
Phalloidin is a cyclic heptapeptide toxin described by APExBIO as a high-affinity binder and stabilizer of filamentous actin. The available evidence here is limited to supplier documentation, so its conceptual relevance to cytoskeleton visualization is documented, while claims about biological outcomes, assay performance, and broader applicability remain unverified.
-
AEBSF.HCl and the Limits of Necroptosis Evidence
2026-10-13
The cited necroptosis study implicates MLKL-driven lysosomal membrane permeabilization and cathepsin B in cell death. AEBSF.HCl is described by its supplier as a broad-spectrum serine protease inhibitor, but the supplied evidence does not show that it was used in the study or that it directly inhibits the cathepsin-dependent mechanism reported there.
-
JC-1 Assays and Gold(I)-Glabridin Research
2026-10-13
A 2025 preclinical study reported that a glabridin–gold(I) complex altered tumor and immune-cell features in liver cancer models. The supplied evidence does not establish that a JC-1 assay kit was used, nor does it show that mitochondrial membrane potential changes caused the reported immunological effects. JC-1 fluorescence is therefore best treated as a potential mitochondrial stress readout, not as standalone proof of apoptosis or therapeutic efficacy.
-
TECPR1 and the Limits of Lysosomal Repair Evidence
2026-10-12
A 2026 Cell Research study proposes that TECPR1 helps repair damaged lysosomes during energy stress by coordinating PI4P-dependent membrane tubulation with KIF1A. The evidence spans cell models, a reconstituted membrane system, and a mouse metabolic-disease model, but its relevance to human disease and broader lysosomal biology remains unestablished. Protease inhibitor products may support sample integrity during analysis, yet they do not constitute evidence for the proposed repair mechanism.
-
MLKL, Lysosomes and Necroptosis: Study Overview
2026-10-12
A source-grounded overview of how the cited study links MLKL polymerization to lysosomal membrane permeabilization, cathepsin B release and necroptotic cell death—and why those findings should not be treated as evidence about AEBSF.HCl.
-
How MLKL Polymers Drive Necroptosis
2026-10-11
Liu and colleagues report that activated MLKL moves to lysosomal membranes, where its polymerization promotes lysosomal membrane permeabilization before plasma membrane rupture. The resulting release of cathepsin B provides a mechanistic link between MLKL polymer formation and execution of necroptotic cell death, while also defining important limits for extrapolation beyond the studied cellular models.
-
Protease Inhibitor Cocktail: Evidence and Limits
2026-10-10
A source-grounded overview of how an EDTA-free protease inhibitor mixture may preserve proteins, what the cited LAG-3 study actually demonstrates, and where product claims, assay interpretation, and biological conclusions must remain separate.
-
O-GlcNAcylation, Wnt Signaling, and Bone Formation
2026-10-09
A 2024 EMBO Reports study identifies O-GlcNAcylation as a metabolic and post-translational mechanism that enables Wnt3a-driven osteoblastogenesis. Its evidence connects Wnt signaling to PDK1 stabilization, aerobic glycolysis, bone formation, and fracture healing while remaining primarily preclinical.
-
LRPPRC–Dasatinib Synergy in OXPHOS-Dependent Tumors
2026-10-09
A 2026 study identifies dasatinib as a synergistic partner for LRPPRC inhibition in cancer cell models. Its central contribution is a dual-genome mechanism: dasatinib preferentially affects nuclear-encoded OXPHOS programs, while LRPPRC inhibition impairs mitochondrial genome-encoded components.
-
Protease Inhibitor Cocktail (MS-SAFE) Overview
2026-10-08
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO), SKU K4001, is an APExBIO-listed reagent described for limiting endogenous proteolysis during protein extraction. No matched paper evidence was provided, so its performance and mass-spectrometry benefits remain unverified here.
-
Glutathione Redox Signals in Hypoxic Tumors
2026-10-08
A mechanistic and translational perspective on how GSH and GSSG measurements can contextualize hypoxia, immunometabolism, oxidative stress, and tumor microenvironment biology without overstating what a bulk redox assay can prove.
-
Milk Extracellular Vesicles in Porcine Intestinal Models
2026-10-07
Wang et al. developed three porcine intestinal stem cell–based model formats to examine how milk-derived extracellular vesicles interact with regionally specified, polarized intestinal epithelium. The study links vesicle uptake to epithelial orientation and intestinal location, while showing that endocytosis inhibitors reduce internalization and that colon-derived models display changes in stemness- and differentiation-associated gene expression.
-
Protease Inhibitors in OXPHOS Cancer Research
2026-10-07
A source-grounded overview of how sample-preservation reagents relate to research on LRPPRC inhibition, dasatinib, and oxidative phosphorylation. The discussion separates findings from interpretation, explains where an EDTA-free protease inhibitor may support protein-analysis workflows, and outlines the evidence limitations that prevent direct claims about therapeutic efficacy or clinical translation.
-
dual-enSERT and In Vivo Enhancer Variant Testing
2026-10-06
Hollingsworth and colleagues introduce dual-enSERT, a two-color reporter framework for comparing human enhancer alleles in the same living mouse context. The study validates known regulatory variants, identifies activity-changing variants among 15 neurodevelopmental candidates, and combines reporter measurements with single-cell transcriptomics to connect enhancer activity with cellular states.